NCT02717208已完成1 期
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Local Tolerability and Pharmacokinetic Characteristics After Administration of Eye-drop HL036 in Healthy Korean Male Volunteers (Phase I)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Adverse Events
研究概览
简要总结
To evaluate the safety, local tolerability and pharmacokinetic characteristics after administration of eye-drop HL036 in healthy Korean male volunteers
详细描述
A total of 10 subjects will be dosed in each group with subjects randomized 8:2 to HL036 or placebo. Three of 10 subjects will be randomized to the sentinel dosing in each group. A safety data review as masking will be performed for 3days prior to the other subjects treatment. Treatment of high dose will proceed following a review of safety data from low dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subjects who listened to the description about characteristics of this clinical trial and signed the IRB approved consent form before the whole screening tests
- •Healthy Korean males volunteers who are 20 to 50 years old at screening procedure
排除标准
- •Subjects who have a history of tuberculosis or have a positive Quantiferon Test
- •Subjects who have treated live vaccine within 8 weeks prior to the first day of dosing or have a plan to treat it before the end of study
- •Subjects who have presence or history of significant hepatic(including hepatitis B or C) , renal, neurological, immunological, respiratory , endocrine or hemato•oncology, cardiovascular, psychiatric disease
- •Subjects who have presence or history of ophthalmological examination by the following
- •① History of ocular disease including keratitis, uveitis, retinitis, dry eye, strabismus or had suspected symptoms or signs
- •② Subjects who are under 20/40 of corrected visual acuity at screening
- •③ Subjects with a history of ocular surgery ( including subjects who had laser surgery in the previous 6 month from screening)
- •④ Subjects who had contact lens wear within 1 month or had side effects after wearing, unwilling to discontinue wear during the study period
- •⑤ Abnormalities following other ophthalmological examination
- •Subjects who have a history of allergy to anti-TNF drug(infliximab, adalimumab, etanercept) or any similar product
- •Subjects who had a history of drug abuse or a positive of drug abuse at urine test
- •Subjects who have taken any prescribed drugs, herbal agents within 2 weeks or who have taken any over-the-counter (OTC) drugs including artificial tears or vitamins within 1 week prior to the first day of dosing (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
- •Subjects who have participated in another clinical trial or bioequivalence research with an IP within 3 months prior to the first day of dosing.
- •Subjects who donated whole blood within 2 months or component blood within 1 month or who are donated within 1 month prior to the first day of dosing.
- •Subjects who have currently drinks in excess of 21 units per week(1 unit = 10 g of pure alcohol) or would not be able to stop drinking alcohol during the study
- •Subjects who have smoked in the 6 months or has used nicotine product or would not be able to stop smoking during the hospitalization Subjects who planned pregnancy or cannot use established contraceptions (e.g. infertility operation of the subject or partner, intrauterine contraceptive device of the partner, barrier contraception, diaphragm or condom use in combination during the test
- •Subject who are judged as inappropriate for participating in the clinical trial by researcher because of causes including the test result of clinical laboratory
结局指标
主要结局
Adverse Events
时间窗: 1 week
次要结局
- Peak Plasma Concentration (Cmax)(24 hours)
- Area under the plasma concentration versus time curve (AUC)(24 hours)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy ParticipantsHealthyNCT05428696Alexion Pharmaceuticals, Inc.90
已完成
2 期
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic StrokeStrokeNCT02251197Boehringer Ingelheim97
已完成
2 期
A Safety PK/PD Study of SLV337 in Patients With Type 2 DiabetesType 2 DiabetesNCT00924534Abbott Products61
尚未招募
1 期
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy ParticipantsChronic Idiopathic ConstipationNCT06736912HK inno.N Corporation80
招募中
1 期
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401HyperlipidemiaNCT06041165Shanghai Junshi Bioscience Co., Ltd.44